Hemab Therapeutics

Hemab Therapeutics Hemab partners with patients, HCPs, advocacy organizations, and scientists to raise awareness of rare bleeding disorders. Learn more at www.hemab.com.

Overview
In partnership with patients, healthcare professionals, and scientists, Hemab is raising awareness about rare bleeding and clotting disorders, while urgently working to develop better treatment options. Based in Cambridge, Massachusetts, and Copenhagen, Denmark, Hemab is focused on transforming the standard of care for patients with these serious, underserved conditions. The company is ad

vancing a pipeline of innovative therapeutics aimed at addressing high unmet needs in blood clotting disorders like Glanzmann Thrombasthenia (GT), factor VII deficiency, Bernard-Soulier Syndrome, and Von Willebrand Disease. Clinical Trials
At Hemab, we are dedicated to advancing treatments for rare bleeding disorders. We are actively enrolling in a Phase 2 clinical trial of HMB-001, a subcutaneous injection designed to restore clot formation impaired by GT. The study seeks volunteers aged 18 to 65 with a confirmed or suspected diagnosis of GT to evaluate HMB-001’s potential to reduce bleeds. To learn more or enroll, contact [email protected] or visit https://clinicaltrials.gov/study/NCT06211634

06/23/2026

The coagulation cascade is one of the most elegant systems in human biology.

When it works, clotting factors, platelets, and the vascular wall act together to stop bleeding within seconds.

When it is disrupted, the impact can be life-altering — from spontaneous hemorrhage and iron deficiency anemia to transfusion dependence, diminished quality of life, and surgical risk.

Hemab is building a pipeline to reimagine the treatment of serious bleeding and thrombotic disorders. Our therapies are designed to address underlying disease biology — including bispecific antibodies that bridge missing interactions in coagulation and monovalent antibodies that increase endogenous proteins such as Von Willebrand Factor and Factor VIII, and a growing understanding of how to intervene at specific steps in the cascade in well-designed ways.

Learn more about our approach at www.hemab.com/about-us -approach

Note: This post contains forward-looking statements subject to important risks and uncertainties. See our SEC filings for more detail: https://ir.hemab.com/sec-filings/sec-filing/10-q/0001193125-26-234386

06/18/2026

Prophylaxis is a concept most people living with Von Willebrand disease (VWD) have heard about but never reliably experienced, because existing therapies have challenges.

These findings reflect years of research, extensive experimentation, and collaboration across teams working to advance understanding of prophylactic treatment approaches in VWD.

HMB-002 was designed by our scientists to change this. HMB-002 is a monovalent antibody in clinical development that is designed to bind to Von Willebrand Factor (VWF), extending its half-life and increasing levels of VWF while also elevating FVIII levels — leveraging the body's own biology to restore hemostatic balance rather than repeatedly replacing what's missing.

HMB-002 delivers all of this with subcutaneous dosing.

📖 The preclinical characterization is now published in the American Society of Hematology’s Blood Advances: https://ashpublications.org/bloodadvances/article/10/7/2551/566205/HMB-002-a-monovalent-antibody-that-elevates

Note: This post contains forward-looking statements subject to important risks and uncertainties. See our SEC filings for more detail: https://ir.hemab.com/sec-filings/sec-filing/10-q/0001193125-26-234386

06/15/2026

The burden of chronic bleeding disorders goes far beyond each bleed.

People living with underserved bleeding disorders such as Glanzmann thrombasthenia (GT), Von Willebrand disease (VWD), and Factor VII deficiency (FVIID) often face a significant psychosocial burden alongside their physical bleeding burden.

Natural history studies such as GT360, VWD360, and FVIID360 reveal the strong psychosocial burden of living with these conditions: impacting work, school, relationships, and day-to-day life.

At Hemab, we’re committed to understanding the full lived experience, including emotional and social challenges, so people living with these conditions feel supported and seen.

06/12/2026

The need for blood is constant. The supply isn’t.

Every 2 seconds, someone in the U.S. needs blood or platelets, and yet only about 3% of eligible people donate each year.

For people living with underserved coagulation disorders, access to safe blood products can be life‑saving.

Blood donors and the teams that collect, process, and distribute supplies help ensure that people facing severe and unpredictable bleeding have access to the support they need. Their generosity and commitment are essential to emergency care.

In honor of World Blood Donor Day on Sunday, June 14, consider donating if you’re able. One decision can help ensure care is there when it’s needed most: https://www.redcrossblood.org/donate-blood/how-to-donate/how-blood-donations-help/blood-needs-blood-supply.html

06/10/2026

Coagulation depends on every piece working in concert. Where it fails determines everything.

✓ Glanzmann thrombasthenia: The platelet surface is missing its key protein: GPIIb/IIIa. Platelets arrive at the injury site but can’t stick together to form clots or stabilize bleeds.

✓ Von Willebrand disease: von Willebrand factor, the protein that tethers platelets to injured vessels and stabilizes Factor VIII, is deficient or dysfunctional, leading to the most common bleeding disorder worldwide.

✓ Factor VII deficiency: Factor VII is the first coagulation factor activated by tissue injury. Without it, the coagulation cascade stalls at the beginning.

While the causes are different, the lived experience isn’t. Years without a diagnosis, little to prevent the next bleed, and lives quietly rearranged around a condition that medicine largely looked past.

If you’re a clinician who treats one of these underserved diseases, or a researcher studying them, we’d like to hear from you: https://www.hemab.com/contact-us

What an incredible morning! Stepping up to the Nasdaq podium today as COAG is a feeling we won't soon forget.The opening...
05/06/2026

What an incredible morning! Stepping up to the Nasdaq podium today as COAG is a feeling we won't soon forget.

The opening bell is another call to advance treatments for underserved blood coagulation disorders.

Today is entirely about accelerating our ability to build for the patients who urgently need better options. Thank you to everyone working alongside us to make it happen.

05/01/2026

Every step we take at Hemab is driven by a single purpose: reaching the overlooked patients who have been waiting decades for better blood coagulation treatments.

Today as we are officially a Nasdaq-listed company (COAG), it isn't about celebrating a corporate victory, it's about fueling the hard work ahead to bring those much-needed treatments to life.

We share this day with the dedicated employees, partners, stakeholders and patient community members working alongside us to make meaningful progress towards treatments.

Read more: https://ir.hemab.com/news-releases/news-release-details/hemab-therapeutics-announces-pricing-upsized-initial-public

04/08/2026

Horizon blindness is what happens when patients stop expecting better: a rational response when nothing better has been offered.

GT360, VWD360, and FVIID360 – our natural history studies – were designed to ask the questions that have historically gone unasked. The lived experiences reshaped how we think about disease burden: in GT360, 88% of participants had bled in the past week and approximately 30% met criteria for symptomatic depression. And across the board, quality of life was further driven down by anxiety.

Patient voices make better therapies possible, and our natural history studies are where it all begins. At Hemab, we’re working toward a future where the horizon feels visible again: https://www.hemab.com/about-us -approach

Iron deficiency and iron deficiency anemia disproportionately affect Black women of reproductive age — with prevalence r...
04/07/2026

Iron deficiency and iron deficiency anemia disproportionately affect Black women of reproductive age — with prevalence rates up to five times higher than the general female population.

They're told their periods are "just heavy." They research and buy iron supplements. They schedule their lives around heavy bleeding episodes that never got diagnosed.

When an underserved bleeding disorder presents as a common symptom, it gets normalized. When it's normalized in a community already facing diagnostic delays, our ability to close gaps in health equity disappears entirely.

April is National Minority Health Month. This week is Black Maternal Health Week. Both exist because the same women keep falling through the same gaps. And today, World Health Day, is a reminder that bleeding disorders drive global health burdens like iron deficiency and anemia and these remain largely unrecognized.

For a healthier world tomorrow, recognizing the overlooked and getting to a diagnosis of bleeding disorders is a critical first step.

Address

101 Main Street
Cambridge, MA
02142

Website

Alerts

Be the first to know and let us send you an email when Hemab Therapeutics posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Hemab Therapeutics:

Shortcuts

Share

Category